SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

U.S. Markets open in 8 hrs 31 mins

Sanofi (SNY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
44.67+0.31 (+0.70%)
At close: 4:01PM EDT
People also watch
NVSGSKAZNLLYNVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close44.36
Open44.76
Bid0.00 x
Ask0.00 x
Day's Range44.55 - 44.88
52 Week Range36.81 - 45.07
Volume1,039,038
Avg. Volume1,710,006
Market Cap110.4B
Beta0.76
PE Ratio (TTM)23.41
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.58 (3.54%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Will Sanofi (SNY) Prove to be a Suitable Value Stock?
    Zacks15 hours ago

    Will Sanofi (SNY) Prove to be a Suitable Value Stock?

    Value investing is easily one of the most popular ways to find great stocks in any market environment.

  • PR Newswire17 hours ago

    Sanofi Genzyme Extends its Multiple Myeloma Journey Partners Program to Cities Nationwide to Help Improve Patient Outcomes through Peer-to-Peer Education

    CAMBRIDGE, Mass., March 22, 2017 /PRNewswire/ -- Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the extension of the Multiple Myeloma Journey Partners Program that leverages storytelling as a tool to improve the patient experience with multiple myeloma. Journey Partners are multiple myeloma patients that have experienced similar emotions, faced the same challenges and asked the same questions about living with the disease. "Sanofi Genzyme created the Multiple Myeloma Journey Partners Program to let multiple myeloma patients know they are not alone and to provide educational resources and services that help patients and families navigate their journey to achieve the best possible outcomes," says Bhavesh Ashar, Vice President and General Manager of US Oncology, Sanofi Genzyme.

  • Investopediayesterday

    Sanofi and Regeneron Sue Amgen over Eczema Drug

    Sanofi and Regeneron want a court to rule that their eczema drug Dupixent doesn't infringe Amgen's patent.